Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

About this item

Title

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

Content partner

University of Otago

Collection

Otago University Research Archive

Description

The optimal duration of androgen suppression for men with locally advanced prostate cancer receiving radiotherapy with curative intent is yet to be defined. Zoledronic acid is effective in preventing androgen suppression-induced bone loss, but its role in preventing castration-sensitive bone metastases in locally advanced prostate cancer is unclear. The RADAR trial assessed whether the addition of 12 months of adjuvant androgen suppression, 18 months of zoledronic acid, or both, can improve o...

Read more

Format

Research paper

Research format

Scholarly text / Journal article

Thesis level

Article

Date created

2019-02-01

Creator

Denham, James W / Joseph, David / Lamb, David S / Spry, Nigel A / Duchesne, Gillian / Matthews, John / Atkinson, Chris / Tai, Keen-Hun / Christie, David / Kenny, Lizbeth / Turner, Sandra / Gogna, Nirdosh Kumar / Diamond, Terry / Delahunt, Brett / Oldmeadow, Chris / Attia, John / Steigler, Allison

URL

https://hdl.handle.net/10523/28480

Related subjects

Aged / Androgen Antagonists - administration & dosage / Australia / Brachytherapy - methods / Cause of Death / Combined Modality Therapy / Disease-Free Survival / Dose-Response Relationship, Drug / Drug Administration Schedule / Follow-Up Studies / Humans / Male / Middle Aged / Neoplasm Grading / Neoplasm Invasiveness - pathology / Neoplasm Staging / New Zealand / Prostate-Specific Antigen - blood / Prostatic Neoplasms - mortality / Prostatic Neoplasms - pathology / Prostatic Neoplasms - therapy / Risk Assessment / Survival Analysis / Time Factors / Treatment Outcome / Zoledronic Acid - administration & dosage

What is the copyright status of this item?

All Rights Reserved

This item is all rights reserved, which means you'll have to get permission from University of Otago before using it.

What can I do with this item?

You must always check with University of Otago to confirm the specific terms of use, but this is our understanding:

Non-infringing use

NZ Copyright law does not prevent every use of a copyright work. You should consider what you can and cannot do with a copyright work.

No sharing

You may not copy and/or share this item with others without further permission. This includes posting it on your blog, using it in a presentation, or any other public use.

No modifying

You are not allowed to adapt or remix this item into any other works.

No commercial use

You may not use this item commercially.